^
    Back
    Association details:
    Biomarker:BRAF V600E
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:ulixertinib (BVD-523) (ERK2 inhibitor, ERK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2022
    Title:

    Updated clinical outcomes from ULI-EAP-100, an intermediate expanded access program for ulixertinib (BVD-523).

    Published date:
    05/26/2022
    Excerpt:
    ULI-EAP-100 (NCT04566393) is an ongoing intermediate expanded access protocol (EAP) that offers ulixertinib to US patients with advanced solid tumors harboring MAPK pathway alterations...Four pts attained clinical benefit including BRAF V600E PDAC and glioblastoma pts on monotherapy for 413 and 128 days, respectively.
    DOI:
    10.1200/JCO.2022.40.16_suppl.e15101
    Trial ID:
    NCT04566393